Fig. 1: TMAO upregulates PRMT5 and VCAM-1 expression in rat VSMC.
From: PRMT5 critically mediates TMAO-induced inflammatory response in vascular smooth muscle cells
A VSMC were treated with different concentrations of TMAO (100–2000 μM) for 24 h. Subsequently, cell viability was determined using 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) assay and quantitative analysis of cell viability. B VSMC were treated with TMAO (600 μM) for indicated periods (4–48 h), and cell viability was detected using MTT assay and quantitative analysis of cell viability. C VSMC were treated for indicated concentrations of TMAO for 24 h. Representative blots and quantitative analysis of VCAM-1 and PRMT5. The protein expression level was normalized to β-actin. D VSMC were treated with TMAO (600 μM) for indicated periods. Representative blots and quantitative analysis of VCAM-1 and PRMT5. The protein expression level was normalized to β-actin. Data shown are means ± SD, n = 6 per group from three independent experiments. **P < 0.01, ***P < 0.001 using a one-way ANOVA followed by Tukey’s post hoc test.
